These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 12202891)

  • 41. [Costs of population cervical cancer screening program in Poland between 2007-2009].
    Spaczyński M; Karowicz-Bilinska A; Kedzia W; Molińska-Glura M; Seroczyński P; Januszek-Michalecka L; Rokita W; Nowak-Markwitz E
    Ginekol Pol; 2010 Oct; 81(10):750-6. PubMed ID: 21117303
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [The cost of screening for breast and cervical cancer in France].
    Watt S
    Bull Cancer; 2003 Nov; 90(11):997-1004. PubMed ID: 14706904
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Cost-benefit analysis of a population-based cervical cancer screening program designed for Cantabria].
    Ramos-Barrón MÁ; Vázquez-Rodríguez JA; García-Garrido AB
    Semergen; 2014 Sep; 40(6):296-304. PubMed ID: 24534799
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Cancer screening in Hungary: World Bank supported model programs].
    Bodó M; Döbrössy L; Liszka G; Ottó S; Péter Z
    Orv Hetil; 1997 Jul; 138(28):1801-4. PubMed ID: 9280875
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.
    Saadatmand S; Tilanus-Linthorst MM; Rutgers EJ; Hoogerbrugge N; Oosterwijk JC; Tollenaar RA; Hooning M; Loo CE; Obdeijn IM; Heijnsdijk EA; de Koning HJ
    J Natl Cancer Inst; 2013 Sep; 105(17):1314-21. PubMed ID: 23940285
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-effective policies for cervical cancer screening. An international review.
    Fahs MC; Plichta SB; Mandelblatt JS
    Pharmacoeconomics; 1996 Mar; 9(3):211-30. PubMed ID: 10160098
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Mammography screening in Germany: how, when and why?].
    Bick U
    Rofo; 2006 Oct; 178(10):957-69. PubMed ID: 17021975
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Cost-effectiveness of breast cancer screening in women on dialysis.
    Wong G; Howard K; Chapman JR; Craig JC
    Am J Kidney Dis; 2008 Nov; 52(5):916-29. PubMed ID: 18789566
    [TBL] [Abstract][Full Text] [Related]  

  • 49. To what extent is women's economic situation associated with cancer screening uptake when nationwide screening exists? A study of breast and cervical cancer screening in France in 2010.
    Menvielle G; Richard JB; Ringa V; Dray-Spira R; Beck F
    Cancer Causes Control; 2014 Aug; 25(8):977-83. PubMed ID: 24842393
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The impact of screening on cancer incidence and mortality in Missouri, USA, 2004-2013.
    Yoshida Y; Schmaltz CL; Jackson-Thompson J; Simoes EJ
    Public Health; 2018 Jan; 154():51-58. PubMed ID: 29197686
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Use of cancer screening services in Greece and associated social factors: results from the nation-wide Hellas Health I survey.
    Dimitrakaki C; Boulamatsis D; Mariolis A; Kontodimopoulos N; Niakas D; Tountas Y
    Eur J Cancer Prev; 2009 Jun; 18(3):248-57. PubMed ID: 19491613
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Italian cancer figures--Report 2015: The burden of rare cancers in Italy.
    ; Busco S; Buzzoni C; Mallone S; Trama A; Castaing M; Bella F; Amodio R; Bizzoco S; Cassetti T; Cirilli C; Cusimano R; De Angelis R; Fusco M; Gatta G; Gennaro V; Giacomin A; Giorgi Rossi P; Mangone L; Mannino S; Rossi S; Pierannunzio D; Tavilla A; Tognazzo S; Tumino R; Vicentini M; Vitale MF; Crocetti E; Dal Maso L
    Epidemiol Prev; 2016; 40(1 Suppl 2):1-120. PubMed ID: 26951748
    [TBL] [Abstract][Full Text] [Related]  

  • 53. History, development and future of cancer screening in Australia.
    Olver IN; Roder D
    Public Health Res Pract; 2017 Jul; 27(3):. PubMed ID: 28765858
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effectiveness of population-based service screening with mammography for women ages 40 to 49 years with a high or low risk of breast cancer: socioeconomic status, parity, and age at birth of first child.
    Hellquist BN; Czene K; Hjälm A; Nyström L; Jonsson H
    Cancer; 2015 Jan; 121(2):251-8. PubMed ID: 25242087
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cost-effectiveness and budget impact analysis of a population-based screening program for colorectal cancer.
    Pil L; Fobelets M; Putman K; Trybou J; Annemans L
    Eur J Intern Med; 2016 Jul; 32():72-8. PubMed ID: 27157827
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Nationwide screening program for breast and cervical cancers in Hungary: special challenges, outcomes, and the role of the primary care provider.
    Kolozsvári LR; Langmár Z; Rurik I
    Eur J Gynaecol Oncol; 2013; 34(5):419-24. PubMed ID: 24475575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cost-effectiveness of screening for common cancers.
    Wagner JL
    Cancer Metastasis Rev; 1997; 16(3-4):281-94. PubMed ID: 9433640
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Variation in average costs among federally sponsored state-organized cancer detection programs: economies of scale?
    Mansley EC; Duñet DO; May DS; Chattopadhyay SK; McKenna MT
    Med Decis Making; 2002; 22(5 Suppl):S67-79. PubMed ID: 12369233
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Early withdrawal from cervical cancer screening: the question of cost-effectiveness.
    Philips Z; Whynes DK
    Eur J Cancer; 2001 Sep; 37(14):1775-80. PubMed ID: 11549431
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The disease burden of colorectal cancer in Hungary.
    Boncz I; Brodszky V; Péntek M; Agoston I; Nagy Z; Kárpáti K; Kriszbacher I; Fuszek P; Gulácsi L
    Eur J Health Econ; 2010 Jan; 10 Suppl 1():S35-40. PubMed ID: 20012135
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.